What really matters - response and resistance in cancer therapy

References

[1] Kamat AM,Efstathiou JA,Malmström PU.Bladder cancer..Lancet2016;388:2796-810

[2] Harbeck N.Breast cancer..Lancet2017;389:1134-50

[3] Iacobucci I.Genetic basis of acute lymphoblastic leukemia..J Clin Oncol2017;35:975-83 PMCID:PMC5455679

[4] Litwin MS.The diagnosis and treatment of prostate cancer: a review..JAMA2017;317:2532-42

[5] Herbst RS,Boshoff C.The biology and management of non-small cell lung cancer..Nature2018;553:446-54

[6] Lim SH.Optimizing therapy in advanced-stage Hodgkin lymphoma..Blood2018;131:1679-88

[7] Pierorazio PM,Black PC,Heidenreich A.Non-risk-adapted surveillance for stage I testicular cancer: critical review and summary..Eur Urol2018;73:899-907

[8] Steeg PS.Targeting metastasis..Nat Rev Cancer2016;16:201-18

[9] Paul CD,Konstantopoulos K.Cancer cell motility: lessons from migration in confined spaces..Nat Rev Cancer2017;17:131-40 PMCID:PMC5364498

[10] Hamidi H.Every step of the way: integrins in cancer progression and metastasis..Nat Rev Cancer2018;18:533-48

[11] Sopik V,Giannakeas V.Why have ovarian cancer mortality rates declined? Part III. Prospects for the future..Gynecol Oncol2015;138:757-61

[12] Erben V,Schrotz-King P.Metabolomics biomarkers for detection of colorectal neoplasms: a systematic review..Cancers (Basel)2018;10:E246 PMCID:PMC6116151

[13] Li J,Yu X,Yang G.Clinical applications of liquid biopsy as prognostic and predictive biomarkers in hepatocellular carcinoma: circulating tumor cells and circulating tumor DNA..J Exp Clin Cancer Res2018;37:213 PMCID:PMC6122633

[14] Loke SY.The future of blood-based biomarkers for the early detection of breast cancer..Eur J Cancer2018;92:54-68

[15] Sawada T,Nakata T,Takasugi N.Mass screening for neuroblastoma in infants in Japan. Interim report of a mass screening study group..Lancet1984;324:271-3

[16] Shinagawa T,Katanoda K,Ito Y.The incidence and mortality rates of neuroblastoma cases before and after the cessation of the mass screening program in Japan: a descriptive study..Int J Cancer2017;140:618-25

[17] Gøtzsche PC.Screening for breast cancer with mammography..Cochrane Database Syst Rev2013;CD001877

[18] Bleyer A.Screening mammography: update and review of publications since our report in the New England Journal of Medicine on the magnitude of the problem in the United States..Acad Radiol2015;22:949-60

[19] Ripping TM,Verbeek ALM,Broeders MJM.Quantifying overdiagnosis in cancer screening: a systematic review to evaluate the methodology..J Natl Cancer Inst2017;109:doi: 10.1093/jnci/djx060

[20] Wallis MG.How do we manage overdiagnosis/overtreatment in breast screening?.Clin Radiol2018;73:372-80

[21] DeVita VT Jr.A history of cancer chemotherapy..Cancer Res2008;68:8643-53

[22] Zaffiri L,Toledo-Pereyra LH.History of antibiotics. From salvarsan to cephalosporins..J Invest Surg2012;25:67-77

[23] Holohan C,Longley DB.Cancer drug resistance: an evolving paradigm..Nat Rev Cancer2013;13:714-26

[24] Zaffiri L,Toledo-Pereyra LH.History of antibiotics: from fluoroquinolones to daptomycin (Part 2)..J Invest Surg2013;26:167-79

[25] De Clercq E.Approved antiviral drugs over the past 50 years..Clin Microbiol Rev2016;29:695-747 PMCID:PMC4978613

[26] Sachs JR,Gadamsetty S,de Alwis DP.Optimal dosing for targeted therapies in oncology: drug development cases leading by example..Clin Cancer Res2016;22:1318-24

[27] Wong KM,Eckhardt SG.The changing landscape of phase I trials in oncology..Nat Rev Clin Oncol2016;13:106-17

[28] McCarthy MW,Cornely OA,Walsh TJ.Novel agents and drug targets to meet the challenges of resistant fungi..J Infect Dis2017;216:S474-83

[29] Gatzka MV.Targeted tumor therapy remixed-an update on the use of small-molecule drugs in combination therapies..Cancers (Basel)2018;10:E155 PMCID:PMC6025289

[30] Kavanagh S,Lipton JH.Emerging alternatives to tyrosine kinase inhibitors for treating chronic myeloid leukemia..Expert Opin Emerg Drugs2018;23:51-62

[31] Kleczko EK.Mechanisms of rapid cancer cell reprogramming initiated by targeted receptor tyrosine kinase inhibitors and inherent therapeutic vulnerabilities..Mol Cancer2018;17:60 PMCID:PMC5817864

[32] Larionov AA.Current therapies for human epidermal growth factor receptor 2-positive metastatic breast cancer patients..Front Oncol2018;8:89 PMCID:PMC5894159

[33] Sharma GG,Mologni L,Gambacorti-Passerini C.Tumor resistance against ALK targeted therapy-where it comes from and where it goes..Cancers (Basel)2018;10:E62 PMCID:PMC5876637

[34] Soverini S,Bavaro L,Martinelli G.Chronic myeloid leukemia: the paradigm of targeting oncogenic tyrosine kinase signaling and counteracting resistance for successful cancer therapy..Mol Cancer2018;17:49 PMCID:PMC5817796

[35] Tomasello C,Napolitano M,Grizzi G.Resistance to EGFR inhibitors in non-small cell lung cancer: clinical management and future perspectives..Crit Rev Oncol Hematol2018;123:149-61

[36] Bock C.Managing drug resistance in cancer: lessons from HIV therapy..Nat Rev Cancer2012;12:494-501

[37] Garbelli A,Crespan E.How to win the HIV-1 drug resistance hurdle race: running faster or jumping higher?.Biochem J2017;474:1559-77

[38] Britt WJ.New therapies for human cytomegalovirus infections..Antiviral Res2018;159:153-74

[39] Hamers RL,Holmes CB.HIV drug resistance in low-income and middle-income countries..Lancet HIV2018;5:e588-96

[40] Anderson R.Immune dysregulation in cancer patients undergoing immune checkpoint inhibitor treatment and potential predictive strategies for future clinical practice..Front Oncol2018;8:80 PMCID:PMC5874299

[41] Davis MP.Checkpoint inhibitors, palliative care, or hospice..Curr Oncol Rep2018;20:2

[42] Li X,Shi Y.Lessons learned from the blockade of immune checkpoints in cancer immunotherapy..J Hematol Oncol2018;11:31